Back to Stakeholders
Dormant / UnclearResearch, Drug Development & ManufacturingLead program: Phase II

Seelos TherapeuticsOTCQB: SEEL

1 Drug Candidate1 Trial

US clinical-stage biopharmaceutical company developing intranasal racemic ketamine (SLS-002) for major depressive disorder with acute suicidal ideation and PTSD. Completed Phase 2 trials before filing for Chapter 11 bankruptcy in November 2024 and being delisted from Nasdaq; trading continues on OTCQB.

Drug Pipeline

1

SLS-002

Ketamine
Phase IIPaused
Major Depressive Disorder (MDD)PTSD

Intranasal racemic ketamine for MDD with acute suicidal ideation or behaviour (MDSIB) and PTSD. Phase 2 completed; program paused following Chapter 11 bankruptcy filing November 2024.

Quick Facts

Type
Public Biotech
Ticker
OTCQB: SEEL
Lead Stage
Phase II
Website
Visit

Sponsored Trials

1
CompletedII

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Start Date
Compounds
Ketamine, Placebo